Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine

High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respirat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Shohei, Fukunaga, Ami, Tanaka, Akihito, Takeuchi, Junko S., Inoue, Yosuke, Kimura, Moto, Maeda, Kenji, Ueda, Gohzoh, Mizoue, Tetsuya, Ujiie, Mugen, Sugiura, Wataru, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841206/
https://www.ncbi.nlm.nih.gov/pubmed/35183384
http://dx.doi.org/10.1016/j.vaccine.2022.02.052
Descripción
Sumario:High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.

Ejemplares similares